Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy

  1. Gian-Luca McLelland
  2. Thomas Goiran
  3. Wei Yi
  4. Geneviève Dorval
  5. Carol X Chen
  6. Nadine D Lauinger
  7. Andrea I Krahn
  8. Sepideh Valimehr
  9. Aleksandar Rakovic
  10. Isabelle Rouiller
  11. Thomas M Durcan
  12. Jean-François Trempe
  13. Edward A Fon  Is a corresponding author
  1. Montreal Neurological Institute and Hospital, McGill University, Canada
  2. McGill University, Canada
  3. University of Lübeck, Germany

Abstract

Despite their importance as signaling hubs, the function of mitochondria-ER contact sites in mitochondrial quality control pathways remains unexplored. Here we describe a mechanism by which Mfn2, a mitochondria-ER tether, gates the autophagic turnover of mitochondria by PINK1 and parkin. Mitochondria-ER appositions are destroyed during mitophagy, and reducing mitochondria-ER contacts increases the rate of mitochondrial degradation. Mechanistically, parkin/PINK1 catalyze a rapid burst of Mfn2 phosphoubiquitination to trigger p97-dependent disassembly of Mfn2 complexes from the outer mitochondrial membrane, dissociating mitochondria from the ER. We additionally demonstrate that a major portion of the facilitatory effect of p97 on mitophagy is epistatic to Mfn2 and promotes the availability of other parkin substrates such as VDAC1. Finally, we reconstitute the action of these factors on Mfn2 and VDAC1 ubiquitination in a cell-free assay. We show that mitochondria-ER tethering suppresses mitophagy and describe a parkin-/PINK1-dependent mechanism that regulates the destruction of mitochondria-ER contact sites.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all Figures.

Article and author information

Author details

  1. Gian-Luca McLelland

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  2. Thomas Goiran

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Wei Yi

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  4. Geneviève Dorval

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  5. Carol X Chen

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  6. Nadine D Lauinger

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  7. Andrea I Krahn

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  8. Sepideh Valimehr

    Department of Anatomy and Cell Biology, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  9. Aleksandar Rakovic

    Institute of Neurogenetics, University of Lübeck, Lübeck, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Isabelle Rouiller

    Department of Anatomy and Cell Biology, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  11. Thomas M Durcan

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  12. Jean-François Trempe

    Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada
    Competing interests
    The authors declare that no competing interests exist.
  13. Edward A Fon

    McGill Parkinson Program, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
    For correspondence
    ted.fon@mcgill.ca
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5520-6239

Funding

Canadian Institutes of Health Research (Canada Graduate Scholarship)

  • Gian-Luca McLelland

Canadian Institutes of Health Research (Foundation Grant)

  • Edward A Fon

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Ivan Dikic, Goethe University Frankfurt, Germany

Version history

  1. Received: November 8, 2017
  2. Accepted: April 19, 2018
  3. Accepted Manuscript published: April 20, 2018 (version 1)
  4. Version of Record published: April 30, 2018 (version 2)

Copyright

© 2018, McLelland et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 9,605
    views
  • 1,958
    downloads
  • 271
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gian-Luca McLelland
  2. Thomas Goiran
  3. Wei Yi
  4. Geneviève Dorval
  5. Carol X Chen
  6. Nadine D Lauinger
  7. Andrea I Krahn
  8. Sepideh Valimehr
  9. Aleksandar Rakovic
  10. Isabelle Rouiller
  11. Thomas M Durcan
  12. Jean-François Trempe
  13. Edward A Fon
(2018)
Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy
eLife 7:e32866.
https://doi.org/10.7554/eLife.32866

Share this article

https://doi.org/10.7554/eLife.32866

Further reading

    1. Cell Biology
    Makiko Kashio, Sandra Derouiche ... Makoto Tominaga
    Research Article

    Reports indicate that an interaction between TRPV4 and anoctamin 1 (ANO1) could be widely involved in water efflux of exocrine glands, suggesting that the interaction could play a role in perspiration. In secretory cells of sweat glands present in mouse foot pads, TRPV4 clearly colocalized with cytokeratin 8, ANO1, and aquaporin-5 (AQP5). Mouse sweat glands showed TRPV4-dependent cytosolic Ca2+ increases that were inhibited by menthol. Acetylcholine-stimulated sweating in foot pads was temperature-dependent in wild-type, but not in TRPV4-deficient mice and was inhibited by menthol both in wild-type and TRPM8KO mice. The basal sweating without acetylcholine stimulation was inhibited by an ANO1 inhibitor. Sweating could be important for maintaining friction forces in mouse foot pads, and this possibility is supported by the finding that wild-type mice climbed up a slippery slope more easily than TRPV4-deficient mice. Furthermore, TRPV4 expression was significantly higher in controls and normohidrotic skin from patients with acquired idiopathic generalized anhidrosis (AIGA) compared to anhidrotic skin from patients with AIGA. Collectively, TRPV4 is likely involved in temperature-dependent perspiration via interactions with ANO1, and TRPV4 itself or the TRPV4/ANO 1 complex would be targeted to develop agents that regulate perspiration.

    1. Cell Biology
    Yuki Date, Yukiko Sasazawa ... Shinji Saiki
    Research Article Updated

    The autophagy-lysosome pathway plays an indispensable role in the protein quality control by degrading abnormal organelles and proteins including α-synuclein (αSyn) associated with the pathogenesis of Parkinson’s disease (PD). However, the activation of this pathway is mainly by targeting lysosomal enzymic activity. Here, we focused on the autophagosome-lysosome fusion process around the microtubule-organizing center (MTOC) regulated by lysosomal positioning. Through high-throughput chemical screening, we identified 6 out of 1200 clinically approved drugs enabling the lysosomes to accumulate around the MTOC with autophagy flux enhancement. We further demonstrated that these compounds induce the lysosomal clustering through a JIP4-TRPML1-dependent mechanism. Among them, the lysosomal-clustering compound albendazole promoted the autophagy-dependent degradation of Triton-X-insoluble, proteasome inhibitor-induced aggregates. In a cellular PD model, albendazole boosted insoluble αSyn degradation. Our results revealed that lysosomal clustering can facilitate the breakdown of protein aggregates, suggesting that lysosome-clustering compounds may offer a promising therapeutic strategy against neurodegenerative diseases characterized by the presence of aggregate-prone proteins.